Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: MT-II · MT2
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Melanocortin analogue peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Melanocortin activity affecting pigmentation and other physiology.
Evidence and critical reading
Reported scientific and empirical uses
Sexual function · Skin, hair and cosmetics
Handbooks include loading and maintenance schedules. They are documented as reported practice without turning UV exposure or escalation instructions into guide recommendations.
Human evidence
No approved cosmetic tanning indication established. Case reports and product testing concern harms, not proven benefit.
Preclinical evidence
Receptor effects do not establish safe tanning.
Critical reading and limitations
TGA warnings and published cases preclude a safe-tanning claim. Reported nevus changes and serious events require context: a case does not quantify incidence or establish causality on its own. Inconsistent products add exposure uncertainty.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by 2.pdf
100–250 mcg · Total daily amount
- Frequency
- Daily in the comparison table.
- Duration
- Table mentions 2–4-week loading plus maintenance without a detailed regimen.
- Route
- Table lists SC or nasal; the dose is not unambiguously paired with a route.
- Context
- Described tanning use; no UV exposure recommendation.
- Presentation
- Not stated on selected page.
- Interpretation
- Not presented as a standard regimen: route and product ambiguity remain.
manual07 · Page 49 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Reports include priapism and serious systemic events; melanoma reports do not establish an incidence or causal risk estimate.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Melanotan II · 1 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
The official registry record NCT07437560 contains mock, fictional or example-study wording. It is excluded from ordinary trial listings pending source authentication. A registry entry does not establish that a genuine study was conducted or that clinical results exist. · NCT07437560
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- R06
- R33
- R34
- manual07
2.pdf
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- NCT07437560
ClinicalTrials.gov NCT07437560 — source-integrity review hold
October 18, 2026